Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
received:
21
05
2024
accepted:
22
10
2024
revised:
11
10
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
aheadofprint
Résumé
With a prolonging duration of survivorship, patients with multiple myeloma (MM) who receive high-dose chemotherapy and autologous hematopoietic stem cell transplantation (auto-HCT) have an increased risk of secondary malignancy, most concerning acute leukemia. We retrospectively reviewed the records of all patients with MM who underwent auto-HCT between January 1, 2010, and January 1, 2023, who later developed therapy-related acute leukemia (t-AL). Of 1770 patients with MM who underwent auto-HCT, 18 (1.01%) developed t-AL at a mean interval of 60.0 ± 41.3 months after auto-HCT. The patients with t-AL consisted of 9 (50%) with B-cell acute lymphoblastic leukemia (B-ALL), 8 (44.4%) with acute myeloid leukemia (AML), and 1 (5.6%) with acute promyelocytic leukemia (APML). All patients had received an alkylating agent as part of induction, and the majority received lenalidomide as maintenance therapy. Genetic abnormalities of t-AL were consistent with prior reports. Median overall survival from diagnosis of t-AL was 19.5 months. In patients with t-AL who entered CR, long term survival was common. Further research on predisposing conditions to developing t-AL in patients with MM undergoing auto-HCT is warranted.
Identifiants
pubmed: 39478188
doi: 10.1038/s41409-024-02455-4
pii: 10.1038/s41409-024-02455-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Mikhael J, Bhutani M, Cole CE. Multiple myeloma for the primary care provider: a practical review to promote earlier diagnosis among diverse populations. Am J Med. 2023;136:33–41.
doi: 10.1016/j.amjmed.2022.08.030
pubmed: 36150517
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327:464–77.
doi: 10.1001/jama.2022.0003
pubmed: 35103762
Ocio EM, Perrot A, Bories P, San-Miguel JF, Blau IW, Karlin L, et al. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation. Leukemia. 2023;37:1521–9.
doi: 10.1038/s41375-023-01936-7
pubmed: 37316728
pmcid: 10264885
Kaiser MF, Hall A, Walker K, Sherborne A, De Tute RM, Newnham N, et al. Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma. JCO. 2023;41:3945–55.
doi: 10.1200/JCO.22.02567
Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, et al. Idecabtagene Vicleucel for relapsed/refractory multiple myeloma: real-world experience from the myeloma CAR T Consortium. J Clin Oncol. 2023;41:2087–97.
doi: 10.1200/JCO.22.01365
pubmed: 36623248
pmcid: 10082273
Singh S, Sharma R, Singh J, Jain K, Paul D. Autologous stem cell transplantation for multiple myeloma in the novel agent era: Systematic review of Indian data and implications for resource constrained settings. J Cancer Res Ther. 2023;19:S12–19.
doi: 10.4103/jcrt.jcrt_503_22
pubmed: 37147978
Jantunen E, Partanen A, Turunen A, Varmavuo V, Silvennoinen R. Mobilization strategies in myeloma patients intended for autologous hematopoietic cell transplantation. Transfus Med Hemother. 2023;50:438–47.
doi: 10.1159/000531940
pubmed: 37899993
pmcid: 10603622
Teh BW, Harrison SJ, Slavin MA, Worth LJ. Epidemiology of bloodstream infections in patients with myeloma receiving current era therapy. Eur J Haematol. 2017;98:149–53.
doi: 10.1111/ejh.12813
pubmed: 27717026
Waszczuk-Gajda A, Penack O, Sbianchi G, Koster L, Blaise D, Reményi P, et al. Complications of autologous stem cell transplantation in multiple myeloma: results from the CALM study. J Clin Med. 2022;11:3541.
doi: 10.3390/jcm11123541
pubmed: 35743620
pmcid: 9225651
Patel SS, Rybicki LA, Corrigan D, Bolwell B, Dean R, Liu H, et al. Prognostic factors for mortality among day +100 survivors after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2018;24:1029–34.
doi: 10.1016/j.bbmt.2018.01.016
Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leuk Res. 2018;74:130–6.
doi: 10.1016/j.leukres.2018.07.016
pubmed: 30055822
pmcid: 6219911
Taylor PR, Jackson GH, Lennard AL, Hamilton PJ, Proctor SJ. Low incidence of myelodysplastic syndrome following transplantation using autologous non-cryopreserved bone marrow. Leukemia. 1997;11:1650–3.
doi: 10.1038/sj.leu.2400795
pubmed: 9324284
Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood. 2000;95:3273–9.
doi: 10.1182/blood.V95.11.3273
pubmed: 10828005
Kallen ME, Koka R, Singh ZN, Ning Y, Kocoglu MH, Badros AZ, et al. Therapy-related B-lymphoblastic leukemia after multiple myeloma. Leuk Res Rep. 2022;18:100358.
pubmed: 36353199
pmcid: 9637917
Yalniz FF, Greenbaum U, Pasvolsky O, Milton DR, Kanagal-Shamanna R, Ramdial J, et al. Characteristics and outcomes of patients with multiple myeloma who developed therapy-related acute myeloid leukemia and myelodysplastic syndrome after autologous cell transplantation. Transpl Cell Ther. 2024;30:205.e1–205.e12.
doi: 10.1016/j.jtct.2023.06.015
Nadiminti K, Sidiqi MH, Meleveedu K, Alkhateeb HB, Hogan WJ, Litzow M, et al. Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2021;11:63.
doi: 10.1038/s41408-021-00454-y
pubmed: 33741897
pmcid: 7979889
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
doi: 10.1182/blood-2016-03-643544
pubmed: 27069254
Mahindra A, Raval G, Mehta P, Brazauskas R, Zhang MJ, Zhong X, et al. New cancers after autotransplantations for multiple myeloma. Biol Blood Marrow Transpl. 2015;21:738–45.
doi: 10.1016/j.bbmt.2014.12.028
Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N. Engl J Med. 2022;387:132–47.
doi: 10.1056/NEJMoa2204925
pubmed: 35660812
pmcid: 10040899
Govindarajan R, Jagannath S, Flick JT, Vesole DH, Sawyer J, Barlogie B, et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol. 1996;95:349–53.
doi: 10.1046/j.1365-2141.1996.d01-1891.x
pubmed: 8904891
Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, et al. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022;140:1753–63.
doi: 10.1182/blood.2021014956
pubmed: 35512188
pmcid: 9837415
McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N. Engl J Med. 2012;366:1770–81.
doi: 10.1056/NEJMoa1114083
pubmed: 22571201
pmcid: 3744390
Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N. Engl J Med. 2012;366:1782–91.
doi: 10.1056/NEJMoa1114138
pubmed: 22571202
McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279–89.
doi: 10.1200/JCO.2017.72.6679
pubmed: 28742454
pmcid: 5652871
Elsallab, Ellithi M, Lunning MA M, D’Angelo, Ma C, Perales MA J, et al. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System. Blood. 2024;143:2099–105.
doi: 10.1182/blood.2024024166
pubmed: 38483155
Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrissette JJD, Caponetti GC, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med. 2024;30:984–9.
doi: 10.1038/s41591-024-02826-w
pubmed: 38266761